Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9447336 | 0.81 | TSHR (0.46) | SHBGESR1ESR2KIF11TAAR1 | |
| SCHEMBL2815949 | 0.79 | MAPT (0.47) | SHBGESR1ESR2KIF11TAAR1 | |
| SCHEMBL3045851 | 0.79 | CYP2A6 (0.33) | SHBGESR1ESR2KIF11TAAR1 | |
| SCHEMBL4673742 | 0.78 | TAAR1 (0.52) | ESR1ESR2TAAR1 | |
| SCHEMBL7583086 | 0.76 | ALDH1A1 (0.43) | KIF11CASP1HSD17B10 | |
| SCHEMBL2254504 | 0.73 | NPC1 (0.48) | SHBG | |
| SCHEMBL11724568 | 0.72 | ESR1 (0.36) | ESR1ESR2TAAR1CASP1HSD17B10 | |
| SCHEMBL4673958 | 0.72 | ALDH1A1 (0.38) | SHBGHSD17B10 | |
| SCHEMBL2815187 | 0.72 | HSD17B10 (0.42) | HSD17B10 | |
| SCHEMBL9081437 | 0.71 | SHBG (0.61) | SHBGESR1ESR2TAAR1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1482935-B1 | THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY | WARNER LAMBERT CO (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1482935-B1 | THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY | WARNER LAMBERT CO (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1482935-A1 | THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY | Warner-Lambert Company LLC (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20030207924-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2003-11-06 | — | — | US | disclosed |
| WO-2003074050-A1 | THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207924-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | SHBG 273/4885ESR1 1171/4885ESR2 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.